Clinical Trials Browser

Recurrence × Drug Therapy × 90 days × Clear all

NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Phase 1/2 Recruiting

Neoplasms, Recurrence